Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168598 | 0.87 | CYP3A4 (0.46) | CYP3A4MAPTTP53SUCNR1GRM2 | |
| SCHEMBL6727825 | 0.87 | CYP3A4 (0.51) | CYP3A4MAPTTP53GRM2PDK1 | |
| SCHEMBL18763021 | 0.84 | GSTO1 (0.48) | MAPTTP53SUCNR1GRM2PDK1 | |
| SCHEMBL29883277 | 0.84 | GSTO1 (0.48) | MAPTTP53SUCNR1GRM2PDK1 | |
| SCHEMBL6731406 | 0.83 | GRM2 (0.55) | CYP3A4MAPTTP53GRM2 | |
| SCHEMBL6730763 | 0.83 | CYP3A4 (0.59) | CYP3A4MAPTTP53GRM2 | |
| SCHEMBL6733385 | 0.81 | CYP3A4 (0.47) | CYP3A4MAPTTP53GRM2UBE2M | |
| SCHEMBL6731186 | 0.80 | MAPT (0.51) | CYP3A4MAPTTP53GRM2POLB | |
| SCHEMBL6733035 | 0.80 | MAPT (0.54) | CYP3A4MAPTTP53GRM2POLB | |
| SCHEMBL6736384 | 0.80 | MAPT (0.48) | CYP3A4MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | CYP3A4 2786/4885MAPT 3885/4885TP53 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.